Vicore is a Swedish rare disease company focused on fibrotic lung disease and related indications. The company currently has two drug development programs, VP01 and VP02. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF), pulmonary fibrosis in systemic sclerosis (SSc) and COVID-19. VP02 is based on a new formulation and delivery route of an existing immunomodulatory compound. VP02 focuses on IPF with regards to both the underlying disease and the severe cough associated with IPF. VP01 and VP02 are also evaluated for other indications within the area of fibrotic lung disease.
The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market.